Company intelligence / Profile preview

Hyperway Pharmaceutical

Chengdu, Sichuan, China

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Hyperway Pharmaceutical is a clinical-stage biotech company with its lead asset HBW-3220, a BTK C481S mutant inhibitor, in Phase IIa for chronic lymphocytic leukemia/SLL, showing a 100% objective response rate in early trials. Another program, HBW-004285, a Nav1.8 inhibitor for pain, is in Phase II.

Therapeutic areas: NeurologyPsychiatryInfectious DiseasesDermatologyOncologyOtherNephrologyImmunology
Modalities: Small moleculeNucleic acidOral peptideProtein degradationMolecular glue
Industry: Biotech

Drug pipeline

9 assets

HBW-3220

8 more assets in the full pipeline.

Request access →

Partnerships

No major pharma partnerships disclosed yet but actively seeking collaborations globally for co-development/licensing opportunities.

Beyond the preview

Go deeper on Hyperway Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hyperway Pharmaceutical.

Explore the full profile